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Edited by Gianni CesareniAbstract Here, we describe the biological activity of ME1, a
mouse single chain Fv fragment (scFv) against the common epi-
tope of mutant p53, which is eﬃciently expressed in mammalian
cells. We found that in vivo interaction of the conformational p53
mutant R175H protein with the scFv resulted in the acquisition
of wild-type p53 characteristics, manifested in trans-activation
of p21, as well as induction of apoptosis. Moreover, antibody
binding leads to abrogation of the mutant p53 mediated ‘‘gain
of function’’ as estimated by downregulation of EGR-1, a tran-
scriptional target of mutant p53. These ﬁndings suggest that
the scFv restores wild-type properties to mutant p53.
 2005 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Activity restoration1. Introduction
Mutations in the p53 tumor suppressor gene are the most
common genetic alterations and occur in more than half of
all human tumors [1]. Most of these alterations are missense
mutations in the DNA-binding core domain responsible for se-
quence-speciﬁc binding of wild-type p53 protein to target
genes.
Involvement of p53 mutants in cancer progression was sug-
gested to be associated with either trans-dominant suppression
of wild-type p53 or a wild-type p53-independent oncogenic
‘‘gain of function’’ [2]. This gain of function involves the abil-
ity of mutant p53 to transactivate or repress speciﬁc genes, dif-
ferent from those aﬀected by wild-type p53, that mediate the
various oncogenic activities of these mutants.
Given the active role of p53 mutants in promoting tumorog-
enicity, eﬀorts are being made to inactivate their function, or
restore wild-type activity employing various strategies re-
viewed in [2,3]. These include the introduction of second site
suppressor mutations that can at least partially restore speciﬁc
DNA binding to mutant p53 [4,5], synthetic peptides derived
from the C-terminus of the p53 protein [6–8], or the CDB3,
a p53-binding protein (p53BP2) derived compound [9], and
low molecular weight compounds, such as CP-31398 [10] and
PRIMA-1 [11].
The ‘‘chaperone like’’ activity of antibodies, which was
shown to modulate protein conformation [12], as well as the*Corresponding author. Fax: +972 3 6409407.
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doi:10.1016/j.febslet.2005.09.031intracellular localization of p53, prompted us to use intracellu-
lar expression of speciﬁc recombinant site-directed antibodies
as a tool for restoring wild-type p53 activity.
More than 90% of the mutations in p53 produce a speciﬁc
conformational change which results in exposure of an epi-
tope, FRHSVV that is otherwise hidden in the hydrophobic
core of the molecule. Previously, we have reported the genera-
tion of a scFv termed ME1 against this epitope [13]. In this
study, we describe the biological activity of the ME1 antibody.
We demonstrate that intracellularly expressed scFv ME1 leads
to restoration of trans-activation activity, enhancement of
apoptosis and abrogation of the ‘‘gain of function’’. These
ﬁndings suggest the importance of such antibodies in the treat-
ment of tumors expressing mutant p53.2. Materials and methods
2.1. Cell lines, plasmids and transfections
Cell line H1299, derived from a human large cell lung carcinoma was
obtained from ATCC. H1299-R175H was derived by stable transfec-
tion of H1299 cells with the pcDNA3-based expression vector con-
structed by G. Blandino carrying the p53-R175H core domain
mutant obtained from B. Vogelstein. SKBR3, derived from a human
breast carcinoma, endogenously expressing the p53 mutation R175H
was obtained from I. Benhar. The reporter construct RGC-Luciferase
was used for Luciferase trans-activation experiments. Both cell lines
were maintained in RPMI (Sigma) medium supplemented with 10%
FCS (Sigma). pc53-SN3 plasmid expressing the wild-type p53 protein
was obtained from B. Vogelstein.
The plasmid pMalC-NN [14] was obtained from I. Benhar. The
pShooter plasmids pCMV/myc/cyto and pCMV/myc/nuc were from
Invitrogen. A plasmid carrying b-galactosidase was co-transfected in
all experiments and used for normalization of transfection eﬃciency.
In all experiments, Fugene 6 (Roche Diagnostic) was used as a trans-
fection reagent, according to the manufacturers recommendations.
2.2. ME1 scFv expression and puriﬁcation
Escherichia coli cells, transformed with pMalC-NN carrying scFv
ME1, were grown in LB medium supplemented with 100 lg/ml ampi-
cillin and 1% (w/v) glucose. When the culture reached A600 of 0.6–0.9,
it was induced with 0.5 mM IPTG at 30 C for four hours. Cell extracts
were prepared in 20 mM Tris–HCl (pH 7.4), 1 mM EDTA and
200 mM NaCl by sonication. The extracts were clariﬁed by centrifuga-
tion at 20000 · g. MBP-scFv fusions were puriﬁed on an amylose resin
column (New England Biolabs, USA).
2.3. Western blot analysis
Cells were lysed in TLB buﬀer (50 mM Tris–HCl pH 7.5, 100 mM
NaCl, 1% Triton X-100, 0.5% deoxycholate and 0.1% SDS) supple-
mented with EDTA free protease inhibitor (Roche). Protein concentra-
tions were determined using the BCA protein assay kit (Pierce)
according to the manufacturers instructions. Equivalent amounts ofation of European Biochemical Societies.
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0.45 Immobilon-P membranes (Millipore), and incubated for 1 h at
room temperature with monoclonal anti-MBP diluted 1:5000 (Sigma,
USA), or rabbit polyclonal anti-EGR-1 1:200 dilution (Santa Cruz
Biotechnology, Inc.), or rabbit polyclonal anti-p21 1:250 dilution (San-
ta Cruz Biotechnology, Inc.) or anti-tubulin 1:1000 (Sigma). All dilu-
tions were in 1% w/v low fat milk. Blots were then incubated with
HRP-conjugated anti-mouse or anti-rabbit IgG 1:5000, for 1 h and
visualized using the ECL kit (Amersham) according to the manufac-
turers instructions.
2.4. Luciferase assays
H1299 cells (4 · 105/well) were transfected with 100 ng of a reporter
plasmid, RGC-Luciferase, in combination with diﬀerent amounts of
plasmids encoding MBP-ME1-cyto and MBP-ME1-nuc, 1 ng of
pcDNA3-human p53-R175H and 100 ng of CMV-b-galactosidase.
Luciferase activity was assayed 48 h post-transfection using the Lucif-
erase reporter assay system (Promega) according to the manufacturers
instructions. Transfections were done in triplicates and normalized to
b-galactosidase activity as an internal transfection control. Lumines-
cence was determined with the Rosys-Anthos Lucy 3 luminometer.
2.5. b-Galactosidase enzyme assay
A sample of 5 ll of cell lysate was mixed with 200 ll of LacZ buﬀer
(60 mM Na2CO3, 40 mM NaH2PO4, 10 mM KCl, 1 mM MgSO4) and
20 ll of substrate (2 mg/ml ONPG in Na2CO3, 40 mM NaH2PO). The
reaction was incubated at 37 C until color was developed and absor-
bance was determined at O.D.420.
2.6. ELISA
Recombinant human wild-type p53 or core domain mutants p53-
R175H, p53-R248H and p53-R273W, expressed in insect cells, were
absorbed to 96-well PVC assay plates (Falcon) overnight at 4 C. Puri-
ﬁed bacterial soluble MBP-ME1 scFv was used. For competition as-
say, the plates were coated with streptavidin overnight at 4 C,
washed and then incubated with biotin-FRHSVV for 1 h. The puriﬁed
MBP-ME1 was pre-incubated with FRHSVV peptide in solution for
one hour at 37 C prior testing.
2.7. Immunoﬂuorescence staining
Cells were grown on cover-slips, ﬁxed with 4% paraformaldehyde
for 30 min at room temperature, washed with PBS and incubated for
5 min with 0.2% Triton and 1% BSA. Following washes with PBS con-
taining 0.5% BSA, the cells were incubated for an additional 1.5 h with
monoclonal anti-MBP (1:1000). The cells were washed and then incu-
bated with FITC-conjugated anti-mouse IgG (Sigma) for 1 h washed
again and examined under a ﬂuorescent microscope.
2.8. Caspase 3/7 activity
Transfections were carried out as described above. The caspase 3/7
kit (Promega) was used according to the manufacturers recommenda-
tions. 105 cells were used per assay and all experiments were done in
triplicates.
2.9. FACS analysis
3 · 105 Cells were grown on 60 mm plates and transfected with dif-
ferent amounts of vector expressing ME1 either in the cytoplasm or the
nucleus. Anti b-galoctosidase scFv was used as control. Cells were
ﬁxed in 70% ethanol, stained with propidium iodide and analyzed on
a Becton Dickinson FACScan (Mountain View, California).3. Results
3.1. Stabilization and expression of soluble active ME1 scFv
antibody
Functional expression of an intracellular antibody in the
reducing milieu of the cytoplasm is a major drawback, as anti-
body fragments expressed in such an environment are strongly
destabilized. Indeed, the biological activity of the generatedscFv antibody directed against the common epitope of mutant
p53, termed ME1 [13], was impaired by its instability. As scFvs
can be stabilized by fusing to MBP [14], we cloned the ME1
scFv sequence into the pMalC-NN plasmid. Upon induction
with IPTG the ME1 scFv fused to MBP accumulated to high
levels in the cells (Fig. 1A, lane 2). A large amount of the fu-
sion protein was found in the soluble fraction (Fig. 1A, lane
3) which was puriﬁed to near homogeneity on an amylose resin
(Fig. 1A, lane 4).
Following puriﬁcation, immunological binding activity of
the MBP-ME1 scFv was tested in a direct and a competitive
ELISA. The wells were coated with the peptide FRHSVV
and the binding capacity of puriﬁed fusion MBP-scFv prior
and following incubation with various amounts of the soluble
FRHSVV peptide was measured. As shown in Fig. 1B, the fu-
sion protein MBP-ME1 scFv retained binding properties to the
common epitope of mutant p53. Pre-incubation of the ME1
antibody with soluble peptide FRHSVV prior testing resulted
in a dose-dependent inhibition of binding to the ELISA plate.
We used recombinant wild-type p53 as well as three recom-
binant p53 mutant proteins p53-R175H, p53-R248W and p53-
R273H, produced in insect cells, in an ELISA assay to test
whether ME1 scFv binds to the epitope when presented in
the context of a whole mutant p53 molecule. Indeed, the anti-
body was able to bind all three mutant proteins but not the
wild-type p53 protein (data not shown).3.2. Intracellular expression of the ME1 scFv gene in
mammalian cells
Biological activity of the ME1 antibody was measured using
two expression vectors. The scFv ME1 was subcloned into the
NcoI–NotI sites of the vectors pCMV/myc/cyto and pCMV/
myc/nuc, which utilize the CMV promoter to derive expression
of the scFv in the cytoplasm or in the nucleus, respectively.
The ability of the scFv ME1 to be expressed in mammalian
cells was determined by transient transfection of p53/
H1299 human lung carcinoma cell line with 10 lg of each of
these two expression vectors. Intracellular expression of ME1
fused to MBP was determined by immunoﬂuorescence staining
with anti-MBP. Abundant accumulation of the fusion anti-
body was observed in the cytoplasm when cells were transfec-
ted with the ME1-cyto and in the nucleus when transfected
with ME1-nuc (Fig. 2A). A band corresponding to the ME1
fusion protein (65 kDa) was detected in a Western blot of
transfected cell lysates using anti-MBP antibody (Fig. 2B).
These results indicate that ME1 scFv fused to MBP can be
expressed both in the cytoplasm and nucleus of mammalian
cells. Furthermore, the expressed fusion scFv proteins are sta-
ble and do not undergo rapid degradation, as previously ob-
served with the non-fused antibody [13].3.3. scFv ME1 facilitates transcriptional activity of mutant p53-
R175H
Wild-type p53 is a transcription factor that was shown to in-
duce expression of target genes through binding to a speciﬁc
DNA responsive element [15].
To examine whether interaction of mutant p53 with scFv
ME1 may restore transcriptional activity to mutant p53, we
used the RGC-Luciferase reporter construct containing several
wild-type p53 responsive elements upstream to the ﬁreﬂy
Fig. 2. Expression of ME1-cyto and ME1-nuc proteins in eukaryotic cells. Immunoﬂuorescent staining using the anti-MBP antibody in transiently
transfected H1299 cells. Cells expressing the antibody in the cytoplasm (A) or the nucleus (B). Western blot analysis of extracts 20 lg/lane, from
H1299 cells transiently transfected with ME1-cyto (1), ME1-nuc (2) or an empty vector (3) probed with anti-MBP (C). Numbers on the right indicate
molecular mass markers.
Fig. 1. Expression, puriﬁcation and binding of MBP-ME1 fusion protein. (A). Aliquots from diﬀerent puriﬁcation steps were separated on a 10%
SDS–polyacrylamide gel. Lane 1, non-induced cell extract; lane 2, induced cell extract; lane 3, induced soluble fraction; lane 4, puriﬁed MBP-ME1
eluted from the amylose resin column. MW, molecular mass marker; MBP-ME1 protein is indicated by the arrow. (B) ELISA using the peptide
FRHSVV as antigen and puriﬁed MBP-ME1 scFv preincubated with the indicated amounts of the same peptide prior testing.
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stably expressing the p53-R175H mutant (Fig. 3A) or H1299
cells transiently expressing R175H (Fig. 3B). Co-transfection
of both cell lines with 100 ng RGC-Luciferase in combination
with diﬀerent amounts of ME1-cyto or ME1-nuc resulted in an
increase in Luciferase activity. When cells were transfected
with anti-b-galactosidase, an irrelevant MBP-scFv plasmid ex-
pressed in the cytoplasm, no eﬀect on Luciferase activity was
observed, indicating that binding of mutant p53 R175H to
the wild-type p53 responsive element following ME1 scFvs
expression is speciﬁc. When cells were co-transfected with
wild-type p53 in combination with the ME1 scFv no diﬀerence
in Luciferase activity was observed compared to levels ob-
tained when cells were transfected with wild-type p53 alone,conﬁrming the speciﬁcity of the ME1 scFv to mutant p53 (data
not shown).
To further substantiate the above observation, we have
examined changes in p21 expression, a ‘‘bona ﬁda’’ wild-type
p53 target gene. To that end, we transfected H1299-R175H
cells, stably expressing mutant p53, with ME1-cyto or ME1-
nuc. Western blot analysis of cell extracts probed with anti-
p21 revealed an elevation in the level of p21 protein when
ME1 scFv was expressed in the nucleus, compared to cells
transfected with an empty plasmid. No change was observed
when the antibody was expressed in the cytoplasm (Fig. 3C).
These results support the conclusion that mutant p53 gained
a wild-type p53 biological activity at least as estimated by these
assays.
Fig. 3. Expression of ME1 restores trans-activation capability to mutant p53. Cells were transfected with RGC-Luciferase reporter gene alone or in
combination with the indicated amounts of ME1-cyto or ME1-nuc, or with an unrelated anti b-galactosidase scFv (b-gal). Luciferase activity was
measured (A) in stably transfected H1299-R175H cells, (B) H1299 cells transiently transfected with 1 ng of pcDNA3-R175H. Cell extracts were
separated on a SDS gel and probed with (C) anti p21 and (D) anti EGR 1. Tubulin was used as a marker for equal amount loading.
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p53
Mutant p53 contributes to the malignant process by acquisi-
tion of novel functions [16]. Transactivation of speciﬁc target
genes that are not activated by wild-type p53 is one such func-
tion. Recently, we found that mutant p53 trans-activates the
Early Growth Response 1 (EGR-1) gene [17]. We examined
whether interaction of mutant p53 with ME1 scFv modiﬁes
this mutant p53-mediated activity. We found that cells stably
expressing mutant p53-R175H when transfected with the scFv
ME1 construct, showed a moderate decrease in ERG-1 protein
level when the antibody was expressed in the cytoplasm,
whereas a dramatic decrease was observed when expressed in
the nucleus (Fig. 3D). This reinforces that exposure of mutant
p53 to ME1 scFv induces changes in the mutant p53 molecule.
3.5. Interaction of mutant p53 with ME1 scFvs induces apoptosis
The apoptotic activity of p53 is a hallmark of this tumor
suppressor gene [18]. Apoptosis is a multistep process which
includes the activation of a cascade of intracellular cysteine
proteases, designated caspases [19]. We used caspase 3/7 activ-
ity as a measure for apoptosis. H1299 cells were co-transfected
with 1 ng p53R175H plasmid in combination with various
amounts of ME1 scFvs. Caspase 3/7 activity was determined
48 h post-transfection. Both ME1 scFv constructs, expressed
in the cytoplasm or in the nucleus, induced a dose-dependent
signiﬁcant increase in caspase 3/7 activity (Fig. 4). Expression
of anti-b-galactosidase scFv in the cytoplasm, a non-relevant
scFv, did not culminate in induction of caspase activity. The
amount of ME1 scFv required for activation of caspase activ-
ity was higher when expressed in the cytoplasm than the
amount needed when expressed in the nucleus. The results ob-
tained in this assay conﬁrmed that mutant p53 seem to lose a
mutant speciﬁc feature upon exposure to ME1 scFv, and thus
exhibit reduced apoptotic blocking activity. To furtherstrengthen these results, we used FACS analysis to determine
the cell cycle proﬁle and degree of apoptosis upon expression
of ME1 in H1299 p53/, H1299 stably expressing R175H
as well as SKBR3, a tumor cell line endogenously expressing
mutant p53-R175H. Expression of ME1 in the nucleus of
either H1299 R175H or SKBR3 cells resulted in enhanced
apoptosis in a dose-dependent manner. The cells were transfec-
ted with 1, 1.7 and 3.3 lg of ME1-nuc which caused an induc-
tion of apoptosis of 17%, 26% and 30%, respectively, in H1299
R175H cells, and 14%, 23% and 32% in SKBR3 cells. The level
of apoptotic cells was unaﬀected in H1299 p53/ cells. No
eﬀect was observed when the cells were transfected with
3.3 lg of a non-relevant b-Gal antibody, or when ME1 was ex-
pressed in the cytoplasm (Fig. 5).4. Discussion
Many of the p53 core domain mutants assume a common
conformational structural change [20]. The extent of the con-
formational change varies in diﬀerent mutants according to
the nature of the missense mutation, resulting in the exposure
of the mutant p53 common epitope FRHSVV to diﬀerent ex-
tents [21]. Taking these ﬁndings into consideration, we have
generated a single chain antibody [13] which speciﬁcally binds
to the mutant p53 common epitope when displayed on the
whole p53 mutant molecules. Mutant p53-R175H is known
to be the most severe conformational p53 mutant causing a
large destabilization eﬀect of the mutant protein, mutation
R248W causes an intermediate destabilization eﬀect, while
the p53-R273H molecule has almost a wild-type conformation.
The binding capacity of scFv ME1 to these three p53 mutants
was found to be in accordance with the extent of their confor-
mational change, where the highest binding was found with
p53-R175H and the lowest binding with p53-R273H.
Fig. 4. Expression of ME1 scFv enhances caspase 3/7 activity. H1299 cells were transiently transfected with 1 ng of pcDNA3-R175H plasmid
without or in combination with various amounts of ME1-cyto (checkered), ME1-nuc (striped), as indicated, 1 ng of pc53-SN3 (black) or 50 ng of anti
b-galactosidase scFv (white) and Caspase activity was determined. Caspase activity in cells transfected with pcDNA3-R175H alone were subtracted
from caspase activity values obtained in each experimental group.
Fig. 5. Expression of ME1 induces apoptosis in cells expressing mutant p53 Cell cycle distribution of H1299 cells, H1299 stably expressing mutant
p53-R175H and SKBR3 cells transfected with 3.3 lg ME1-cyto, 3.3 lg anti b-galoctosidase scFv or various amounts of ME1-nuc, as indicated.
Numbers indicate the percentage of apoptotic cells.
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either in the cytoplasm or in the nucleus, induced binding of
mutant p53 to wild-type p53 responsive elements, which in
turn caused trans-activation of speciﬁc downstream p53 target
genes. Higher amounts of ME1 were required in the cytoplasm
as compared to those in the nucleus for trans-activation. This
can be attributed to the fact that the antibodies exhibit diﬀer-
ent stabilities and protein folding at various sub-cellular com-
partments. Another explanation may be associated with the
eﬃciency of antibody translocation from the cytoplasm to
the nucleus. When expressed in the cytoplasm, it is most likely
that the scFv/p53 complex has to reach the nucleus, where p53
is known to exert its activity. Translocation of the scFv/p53complex to the nucleus may be ineﬃcient, while when ex-
pressed in the nucleus it is not dependent upon p53 traﬃcking.
The diﬀerences in the degree of transcription activation ob-
served in cells stably expressing the mutant p53 protein as
compared to those that were transiently transfected may reﬂect
the diﬀerence in the expression levels as well as the distribution
of mutant p53 protein in these cells.
The ‘‘chaperone like’’ activity of antibodies is well docu-
mented, reviewed in [13], they have been shown to change fold-
ing and unfolding states of proteins upon binding. We assume
that the binding of the scFv ME1 to the p53 mutant protein
rendered the mutant molecule thermodynamically more stable
driving it from an unfolded state to a more favorable one. This
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ical to the wild-type p53 protein. It is now established that the
molecular chaperones HSP70, HSP40 and HSP90 form a com-
plex that can refold denatured proteins as well as protect pro-
teins from unfolding, but they have been also shown to prevent
drug or radiation-dependent apoptosis in cells. Stable interac-
tions were observed between these HSPs and mutant p53 pro-
tein in tumor cells, but not with native wild-type p53. The
binding site for HSPs within the p53 protein was mapped to
the hydrophobic pocket of the core domain, which is exposed
in the unfolded p53 mutant protein but berried in the wild-type
p53 molecule [22]. The epitope that is recognized by scFv ME1
resides in the same hydrophobic pocket and like the HSPs
binds exclusively to mutant p53. Depletion of Hsp70 selec-
tively kills cancer cells not only in cell culture but also in var-
ious tumor xenografts in mice [23]. Recently, it was shown that
depletion of Hsp70-2, a member of the Hsp70 family, resulted
in upregulation of p21 and MIC-1. The expression of both
genes is rapidly induced by a variety of cellular stresses in a
p53-dependent manner [24]. It is tempting to speculate that
binding of scFv ME1 to mutant p53 excludes the binding of
the HSPs to p53, or that scFv ME1 having a high aﬃnity bind-
ing constant may displace the HSPs complex and by this
releasing the inhibition of apoptosis conferred by the HSPs.
Apoptosis is a hallmark for wild-type p53 activity. The link
between p53, caspase activation and apoptosis has been dem-
onstrated [25,26]. We found that co-expression of mutant
p53 with scFv ME1 caused an increase in caspase 3/7 activity,
indicating that binding of the antibody to mutant p53 may re-
sult in transactivation of transcriptional targets leading to
apoptosis. Induction of apoptosis upon expression of scFv
ME1 in the nucleus was demonstrated in cells transfected with
the p53-R175H mutant as well as in a cell line that expresses
this mutation endogenously. Moreover, interaction of mutant
p53 with scFv ME1 caused increased binding to the wild-type
p53 consensus target sequences measured as increase in the
activity of a reporter gene, as well as an increased protein level
of p21 which is involved in regulation of cell cycle progression.
Recently, it was shown that EGR-1 expression is elevated in
cells expressing mutant p53 [17]. This protein was suggested
to activate IGF-II, PDGF-A and PDGF-B involved in cell
proliferation [27–29], BCL-2, ﬁbronectin and NF-jB associ-
ated with survival and cell diﬀerentiation [30–32] and PTEN
as well as TNF-a involved in apoptosis [33,34]. The scFv
ME1 was able to abrogate the mutant p53 ‘‘gain of function’’,
resulting in decreased levels of EGR-1 expression.
These results demonstrated that the scFv ME1 directed to
the common epitope of mutant p53 is speciﬁc for the mutant
form and restores wild-type properties to the mutant p53 pro-
tein. On that basis, we suggest that the use of site-directed anti-
bodies may serve as a tool in p53-based cancer therapy.
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